Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending December 2011, with the report dated December 1, 2011. The filing serves as a notification to the market regarding the Company's total voting rights and capital structure in conformity with Disclosure and Transparency Rule 5.6.1R.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a capital structure notification rather than a financial results report.
Material Changes
The filing details the Company's issued share capital as of November 30, 2011:
- Total issued Ordinary shares: 5,573,171,451 (25p each).
- Treasury shares held: 528,082,927.
- Total voting rights: 5,045,088,524.
No comparative data for prior periods is included in this specific text to determine material changes in share count.
Guidance, Outlook, and Risks
The filing text does not provide guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is strictly limited to the notification of voting rights for shareholder disclosure calculations.
Investor Verification Checklist
- Verify the total number of voting rights (5,045,088,524) for compliance with Financial Services Authority disclosure thresholds.
- Confirm the number of shares held in Treasury (528,082,927) to calculate the free float accurately.
- Note that this filing does not contain financial performance data; refer to Form 20-F or quarterly reports for revenue and earnings.